English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

1Diabetic Clinic *, 2Biochemistry Laboratory*, * Second Pediatric Department University of Athens, “P&A Kyriakou” Children’s Hospital, Athens, Greece. 3Department of Bone and Mineral Metabolism, Institute of Child Health, “Aghia Sophia” Children’s Hospital, Athens, Greece Introduction: Diabetes Mellitus (DM) is a risk factor for reduced bone mass. Several bone metabolic pathways seem to be disrupted in patients with type 1 diabetes mellitus (T1DM). Materials and Methods: We evaluated 40 children and adolescents with T1DM (mean±SD age 13.04±3.53 years, mean±SD T1DM duration 5.15±3.33years) and 40 healthy ageand gendermatched controls (mean±SD age 12.99±3.3years). Osteoprotegerin (OPG), Receptor Activator of Nuclear factor-KappaB Ligand(s-RANKL), Osteocalcin, C-telopeptide crosslinks-CTX, electrolytes, PTH, total 25(OH)D were measured and total body Bone Mineral Density(BMD) was evaluated with dual energy X-ray absorptiometry (DXA).

endocrine abstracts

Higher levels of osteoprotegerin and S-RANKL in children and adolescents with type 1 diabetes mellitus may indicate increased osteoclast activity and predisposition to lower bone mass